Shaping better health
REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary

Decisions 16th January 2018

Checked: not set yet by Next Review: not set yet

At the meeting on the 16th January the following decisions were agreed:

 

New Drug Requests

 

Approved

Trelegy Ellipta® Inhaler (Fluticasone/umeclidinium/vilanterol) (TLS green)

  • Approved for inclusion onto the formulary for maintenance treatment of COPD patients.

 

Not Approved

Saxenda® (Liraglutide)

  • Not approved for inclusion onto the formulary for weight management in patients with obesity.

 

Shared Care Protocols/TLS change in Status

Ciclosporin Eye drops

  • TLS change from red to amber. Shared care protocol agreed.

Leflunomide (rheumatology)

  • Shared care protocol updated.

Sulfasalazine (rheumatology)

  • Shared care protocol updated.

Feraccru®

  • Monitoring responsibilities still being clarified. To be uploaded onto website when agreed.

Methylphenidate

  • Shared care protocol updated to include preferred brands.

Rotigotine

  • Agreed change from TLS amber 1 month to amber no SCP to facilitate timely prescribing by GPs when needed urgently. Shared care protocol to be adapted into prescribing guidance for GPs.

Sodium Valproate/Semi-sodium valproate

  • Existing shared care protocol updated to include sodium valproate as preferred first line choice for bipolar disorder and to include clearer MHRA warnings regarding pregnancy.